This concept isn’t new—in fact, it is the essence of representational state transfer (REST). Instead of converting to a ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Potential to bring nuclear power, scalable eSAF production, and environmental-attribute monetization together into a single, ...

Get the value of an attribute for the first element in the set of matched elements. An attribute value may only be a string. The attributes contains basic information ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare heart condition where abnormal protein deposits stiffen the heart muscle, causing symptoms that resemble normal ageing, including fatigue, ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

Fatigue is one of the most frustrating symptoms of transthyretin cardiac amyloidosis (ATTR-CM). It can reduce your overall quality of life, limiting your ability to complete daily tasks and ...

ATTR-CM can be a life-changing diagnosis, and if youre an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

If you haven’t heard of ATTR-CM before, you’re not alone. A rare disease with potentially fatal consequences, ATTR refers to transthyretin amyloidosis. While this medical terminology can get a little ...

As transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, it can cause more serious problems with the heart and other parts of the body. Talking with your doctor about how the condition may ...

Scoring tools validated to identify people at high risk of having transthyretin amyloid cardiomyopathy (ATTR-CM) still leave room for improvement in diverse populations. The ATTR-CM score and the ...